News » MHRA alert » Co-amoxiclav powder for oral suspension alert
April 21st 2023
Sandoz Limited has advised of an error regarding the sugar content of several batches of co-amoxiclav powder for oral suspension
The affected lines are
Sandoz limited has informed the MHRA that affected products are not sugar free despite the carton stating ‘sugar free’.
All batches supplied since December 2008 have contained a very small quantity of sugar originating from the flavouring. The contained sugars are dextrose and maltodextrin, which are both composed of glucose. The total amount of sugar at the maximum daily doses equates to 204.3 mg in children, 127.8 mg in adults.
Affected batches are not being recalled. Healthcare professionals are advised to inform patients about the error when dispensing subsequent batches or in discussion with patients who may have concerns related to sugar intake or glucose control.
For more information, medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101
For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607
